Moreover, preclinical studies indicates that the attenuation of CCDC6 in lung, pleural, prostate and bladder cancer cells confer sensitivity to inhibitors of PARP1/2 [19], [20], [35], [36]. The gene discussed is PARP1; the disease is urinary bladder carcinoma.